Medeor Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Latest Deal Type
  • Debt - PPP
  • Investors
  • 6

Medeor Therapeutics General Information

Description

Developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.

Contact Information

Formerly Known As
SERC Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 611 Gateway Boulevard
  • Suite 120
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Medeor Therapeutics Timeline

2017201820192020
Financing RoundFinancing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Medeor Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Debt - PPP 29-Apr-2020 000.00 Completed
5. Grant 22-Jan-2018 000.00 000.00 Completed Clinical Trials - General
4. Early Stage VC (Series B) 27-Nov-2017 0000 000.00 00000 Completed Clinical Trials - General
3. Early Stage VC (Series A) 16-Oct-2015 000 000.00 0000 Completed Clinical Trials - General
2. Early Stage VC 02-Oct-2013 $1.55M $2.55M 000.00 Completed Clinical Trials - General
1. Seed Round 11-Jan-2013 $1M $1M 000 Completed Clinical Trials - General
To view Medeor Therapeutics’s complete valuation and funding history, request access »

Medeor Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series A 0,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Seed 1 1,291,667 $0.000100 8% $1.2 $1.2 1x $1.2 4.67%
Seed 1,000,000 $0.000100 8% $1 $1 1x $1 3.61%
To view Medeor Therapeutics’s complete cap table history, request access »

Medeor Therapeutics Executive Team (12)

Name Title Board Seat Contact Info
Edgar Engelman MD Scientific Co-Founder
Robert Lowsky MD Scientific Co-Founder
Samuel Strober MD Scientific Co-Founder
Elizabeth Read MD Senior Vice President, Product Development
Iqbal Husain Ph.D Senior Vice President, Program Management
You’re viewing 5 of 12 executive team members. Get the full list »

Medeor Therapeutics Board Members (6)

Name Representing Role Since
Anand Mehra MD Sofinnova Investments Board Member 000 0000
Chih-Ping Liu Ph.D Self Co-Founder and Chairman 000 0000
Frank Kung Ph.D Vivo Capital Board Member 000 0000
Peter Kolchinsky Ph.D RA Capital Management Board Observer 000 0000
Wei Li Ph.D WuXi Healthcare Ventures Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Medeor Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
California Institute for Regenerative Medicine Government 000 0000 000000 0
6 Dimensions Capital Venture Capital Minority 000 0000 000000 0
RA Capital Management Venture Capital Minority 000 0000 000000 0
Sofinnova Investments Venture Capital Minority 000 0000 000000 0
Vivo Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »